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Opioid analgesics, such as morphine, continue to be the mainstay for managing severe, perioperative and chronic pain 1, 2 . With the staggering prevalence of pain 3 , the broad use of opioids for pain management has increased markedly in the past decades. In the US, this increase in opioid prescriptions has been accompanied by a sharp rise in the incidence of addiction and opioid-related mortality, a phenomenon termed the Opioid Epidemic 4 . Chronic opioid use can result in analgesic tolerance, where analgesic efficacy gradually decreases at fixed drug doses, and paradoxical OIH 5 . Tolerance and OIH are primary drivers of diminished pain control and dose escalation 6, 7 , and therapeutic strategies that can bolster opioid analgesia while mitigating tolerance and OIH are urgently required to improve patients' safety.
Although opioid analgesia results from binding and signaling through MORs 8 present along pain neural circuits 9 , the cell types and receptors mediating tolerance and OIH remain disputed 10, 11 . Tolerance and OIH are adaptive processes that have been proposed to result from complex alterations at the molecular level for MORs, as well as at the synaptic, cellular and circuit levels, in both the peripheral and central nervous systems 12, 13 . Thus, chronic opioids modify neuronal MOR function, including via receptor phosphorylation, signaling, multimerization and trafficking, which may underlie tolerance and OIH 12, 14 . Other studies have suggested that glial cells, and microglia in particular, are essential contributors to opioid tolerance and OIH 15 . Chronic opioids cause microglia and astrocyte activation, and interfering with glial function has been shown to reduce tolerance and OIH 16, 17 . Mechanistically, previous studies have proposed that glial cells express MORs, and that opioid binding to this MOR population activates microglia 10 . However, unequivocal evidence for MOR expression in microglia is lacking 18 , and other studies support the idea that morphine binds to and activates Toll-like receptor 4 (TLR4) and MD-2 signaling in microglia 17, 19 . Adding to the controversy, recent reports found no change in tolerance and OIH in TLR4 knockout (KO) mice 20, 21 . Consequently, the contributions of neuronal versus glial cells, and the molecular mechanisms initiating analgesic tolerance and OIH, remain unresolved.
Opioids alter the properties of MOR-expressing neurons and connected nociceptive circuits at the level of the dorsal root ganglia (DRG), spinal cord dorsal horn and brain (including in the brainstem descending pain control systems) 12, 13 . MOR function in primary afferent nociceptors is of particular interest as an initiation site for tolerance and OIH, as this cell type has been implicated in the development of antinociceptive tolerance, physical dependence and the pronociceptive effects of opioids 5, 22, 23 (Supplementary Note 1) . Indeed, nociceptors undergo and drive pronociceptive plasticity in downstream CNS circuits during persistent pain 24, 25 . Electrophysiological studies have demonstrated that opioids not only depress neurotransmission between nociceptors and dorsal horn neurons 26 , but can also generate maladaptive plasticity, such as long-term potentiation (LTP) 27 .
Opioid-induced LTP is considered to be a critical neural substrate for OIH 24 , and may contribute to tolerance. The pre-28 versus postsynaptic 27 origin of opioid-induced LTP is currently contested, and whether LTP is initiated by MOR activation in nociceptors or spinal neurons is not known. Notably, previous reports have found that ablation of TRPV1 nociceptors not only abolishes opioid-induced LTP 28 , but also reduces tolerance and OIH 29 . Given that we and others have shown that MORs are predominantly expressed by peptidergic TRPV1 nociceptors in DRG 30, 31 , we tested the hypothesis that MOR expressed by nociceptors represents a critical and susceptible element in nociceptive circuits for the initiation of maladaptive mechanisms driving analgesic tolerance and OIH.
RESULTS

Morphine tolerance and OIH, but not microglial activation, require MORs
We first determined whether morphine tolerance and OIH could be dissociated from microglial activation by examining, in parallel, the consequences of morphine treatment on microglial activation, antinociceptive tolerance and OIH in wild-type control and global MOR KO mice. In wild-type mice, chronic morphine treatment produced significant antinociceptive tolerance and OIH (Fig. 1a,b and Supplementary Fig. 1 ), as well as robust microglial activation, as evidenced by increased CD11b density (Fig. 1c,d) , with either a fixed once daily 10 mg/kg dose, or with a twice daily escalating 10-40 mg/kg schedule. Notably, we found that global MOR KO mice treated with the escalating morphine schedule showed considerable microglial activation, but no OIH (Fig. 1b-d) .
Microglia lack Oprm1 mRNA transcript, tagged-MOR protein and MOR immunoreactivity To further investigate the mechanistic separation between OIH and microglial activation, we used immunohistochemistry (IHC), in situ hybridization (ISH) and knock-in mice expressing a fluorescent tagged receptor (MOR-mCherry) to establish which cellular populations express MORs. We found that MORs were expressed in nociceptive Figs. 2  and 3) . However, examination of dorsal horn sections provided no clear evidence for Oprm1 mRNA transcripts (which encodes the canonical seven-transmembrane MOR), anti-MOR immunoreactivity or MOR-mCherry expression in microglia, as identified by CX3CR1-GFP or CD11b immunoreactivity (Fig. 1e-g and Supplementary  Fig. 4 ). Because these results can be explained by the relatively limited sensitivity of histological and imaging techniques, we performed RNA sequencing (RNA-seq) transcriptome profiling on acutely purified, non-cultured spinal microglia from adult mice. We analyzed the expression of exons, as well as that of alternative splice variants and truncated receptors, of Oprm1 (ref. 32) . Unlike in DRG, we did not detect any Oprm1 transcript in purified spinal microglia (Fig. 1h) . RNA-seq reads were mapped in the oppositely oriented Ipcef1 gene, which partially overlaps with Oprm1, but no reads aligned to exons 1-4 of Oprm1 (which are required for the expression of the canonical seven transmembrane protein 32 ). Microglial Oprm1 transcripts mapping to exons 1-4 were also undetectable in mice with chronic neuropathic pain (Fig. 1i, Supplementary Fig. 5 and Supplementary Note 2) or in mice treated with chronic morphine ( Supplementary   Fig. 6 ). We propose that MOR action in neurons likely drives the initiation of the pronociceptive side effects of opioids.
Genetic deletion of MORs from nociceptors does not reduce systemic morphine antinociception
We next sought to identify the specific population of MOR + neurons that promote morphine analgesia, as well as those initiating tolerance and OIH. We took advantage of mouse genetic engineering and generated conditional knockout mice that lack MORs in neurons of the TRPV1 lineage (MOR cKO mice). Mice bearing alleles in which exons 2 and 3 of the Oprm1 gene are flanked by loxP sites were crossed with knock-in mice in which expression of Cre recombinase is driven by the promoter of the Trpv1 gene (Fig. 2a) . TRPV1 was largely restricted to peptidergic nociceptors in adult mice, but was also expressed in non-peptidergic and myelinated nociceptors earlier during development 33 , resulting in Cre-mediated recombination in the great majority of nociceptors (Supplementary Fig. 7) . Consequently, the Oprm1 gene was excised selectively in DRG, and not spinal cord or brain in MOR cKO mice ( Fig. 2b and Supplementary Fig. 8 6.3% (ISH) and 4.2% (IHC) of DRG neurons in MOR cKO mice, as compared with 42.6% (ISH) and 38.7% (IHC) in littermate controls ( Fig. 2c-f ). In the spinal cord, MOR immunoreactivity was strongly decreased in the dorsal horn CGRP + laminae I and II outer ( Fig. 2g-j) , whereas a faint MOR signal persisted in the IB4 + lamina II inner (Fig. 2k,l) , where MOR is expressed in spinal interneurons 34 . Clinically, opioids provide substantive relief of both sensory and affective dimensions of the pain experience. We next evaluated basal nociception, and morphine antinociception in MOR cKO mice, monitoring both nociceptive sensory-reflexive and affectivemotivational behaviors (Online Methods). MOR cKO mice exhibited similar basal nociceptive reflexes and affective-motivational responses to thermal and mechanical stimuli relative to littermate controls ( Fig. 2m-o) . Notably, although acute intrathecal morphine (1 µg) generated robust antinociception in control mice, intrathecal morphine did not produce significant reflexive or affectivemotivational antinociception in MOR cKO mice (Fig. 2p-r) , indicating that spinal opioid antinociception primarily results from presynaptic MOR signaling in nociceptors 26 . By contrast, subcutaneous administration of morphine (10 mg/kg) produced maximal reflexive and affective-motivational antinociception in MOR cKO mice (Fig. 2s-u and Supplementary Note 3) .
Morphine action at nociceptor MORs underlies tolerance and OIH initiation
We next evaluated the development of morphine antinociceptive tolerance and OIH in MOR cKO mice. We treated mice with systemic, fixed-dose morphine (10 mg/kg, subcutaneous) once daily for 10 d. We measured thermal and mechanical nociceptive thresholds and affective-motivational responses to noxious thermal stimuli before and 30 min after each daily injection to evaluate OIH and tolerance, respectively (Fig. 3a-c) . Notably, we found that, although morphine antinociception progressively diminished in littermate controls, morphine retained near full antinociceptive efficacy across all days in MOR cKO mice (Fig. 3d-f) . Moreover, MOR cKO mice developed significantly less OIH than control mice for thermal and mechanical stimuli ( Fig. 3g-i) . This finding suggests that chronic opioid action at MORs expressed by nociceptors triggers the onset of pronociceptive maladaptive plasticity that results in analgesic tolerance and OIH.
Opioids induce a MOR-dependent, presynaptic form of spinal LTP Opioids not only acutely depress synaptic transmission in the spinal cord 26 , but also trigger excitatory plasticity mechanisms 35, 36 , such as LTP 27 . It is unclear whether opioid-induced LTP is initiated by activation of presynaptic or postsynaptic MOR signaling mechanisms. To address this question, we examined synaptic transmission between nociceptors and spinal neurons using spinal cord slices from MOR cKO mice and littermate controls expressing the light-activated channel channelrhodopsin 2 (ChR2) in TRPV1 nociceptors. Using IHC, we confirmed expression of ChR2-eYFP in DRG nociceptor somata and their terminals in lamina I and II outer (Fig. 4a,b) . We made whole-cell recordings from lamina I-II outer neurons with monosynaptic input from ChR2-expressing nociceptors. Bath application of the MOR agonist [D-Ala 2 , N-MePhe 4 , Gly-ol 5 ]-enkephalin (DAMGO; 500 nM) for 5 min induced a rapid depression of light-evoked excitatory postsynaptic currents (EPSCs) in all 15 recorded neurons (52 ± 10.5% inhibition at 5 min of application) (Fig. 4c) . 30 min after washout of DAMGO, EPSC amplitudes were potentiated to 142.2 ± 6.1% of control in 8 of 15 neurons ( Fig. 4c and Supplementary Fig. 9 ), which is consistent with previous reports 27, 28 . This opioid-induced LTP persisted for the duration of the recording. Notably, we found that both DAMGO-induced inhibition and LTP were completely lost in nine of nine recorded neurons from MOR cKO mice (DAMGO inhibition: 98 ± 8.12% of control; DAMGO washout: 96.2 ± 11.9%) (Fig. 4d) . Collectively, these results establish that presynaptic MOR signaling in nociceptors is essential for maladaptive spinal opioid-induced LTP.
Peripheral MOR blockade prevents the onset of morphine tolerance and OIH Our genetic Oprm1 conditional deletion strategy revealed that a loss of MOR signaling in DRG nociceptors prevented the onset of morphine antinociceptive tolerance and OIH. We reasoned that pharmacological blockade of peripheral MOR might similarly alleviate these opioid side effects. In wild-type C57Bl/6J mice, we paired injections of subcutaneous morphine with methylnaltrexone bromide (MNB), a blood-brain-barrier-impermeable MOR antagonist 37 . We assessed the antinociceptive effects of morphine and MNB combination therapy on nociceptive reflexes and affective-motivational behaviors. We used a procedure in which the noxious environment could not be escaped (Fig. 5a-e and Supplementary Fig. 10 ), and monitored pain-like behaviors elicited by acute, punctate mechanical and noxious thermal stimuli ( Fig. 5f-k) . We found that morphine administration significantly reduced nociceptive reflexes (Fig. 5a,b ,c,f and Supplementary Fig. 11a-d) and was effective at alleviating affectivemotivational behaviors (Fig. 5a,d ,e,g and Supplementary Fig. 11a,e-m) . The combination treatment with MNB (0.1-10.0 mg/kg) did not alter morphine antinociceptive effects (Fig. 5a,b,d ,f,g, Supplementary  Fig. 11 and Supplementary Note 4), consistent with our result in MOR cKO mice. We next determined whether MNB can effectively prevent opioid antinociceptive tolerance and OIH by treating mice with a fixed combination of morphine (10 mg/kg) and MNB (0.1-10.0 mg/kg), or morphine alone, once daily for 7 d (Fig. 5) . Notably, although mice treated with morphine alone developed robust antinociceptive tolerance and OIH on both reflexive and affective-motivational measures on day 7 compared with day 1 morphine antinociception and pre-morphine baseline levels, we found that mice co-treated with morphine plus MNB showed a dose-dependent reduction in the onset of tolerance and OIH ( Fig. 5 and Supplementary Fig. 12 ). The administration of MNB combination therapy did not produce any behavioral symptoms of physical withdrawal at any of the tested doses.
MNB and morphine combination therapy provides long-lasting relief from chronic pain Clinically, opioids are prescribed for managing both perioperative and chronic pain. We next assessed the antinociceptive efficacy of morphine and MNB combination therapy in these persistent pain states. We used a tibia fracture and bone pinning model of orthotrauma inflammatory pain and found that, although morphine alone (10 mg/kg) acutely produced antinociception, morphine was no longer effective at reducing nociceptive or affective-motivational orthotrauma pain after 7 d of chronic treatment (Fig. 6a,b,d,e) . In contrast, morphine (10 mg/kg) and MNB (10 mg/kg) combination therapy produced strong antinociception against mechanical reflexive hypersensitivity, as well as against affective-motivational (Fig. 4a,b,d,e and  Supplementary Fig. 13a,b) . Furthermore, no OIH was observed during prolonged use of the combination therapy (Fig. 6a,c,d,f and  Supplementary Fig. 13c) . Similarly, morphine and MNB combination therapy prevented the development of antinociceptive tolerance in the chronic constriction injury (CCI) model of neuropathic chronic pain (Fig. 6g-l) . We did not observe indications of OIH in the control group (CCI + morphine alone), possibly as a result of floor and/or ceiling effects (Fig. 6i,l) . Taken together, our pharmacological results highlight the potential benefit of a peripherally restricted opioid antagonist to limit detrimental pronociceptive side effects that accompany prolonged opioid use. Note 1) . We propose that morphine-induced sensitization of MOR-expressing nociceptors facilitates downstream plasticity in CNS pain and analgesia circuits that promote the development and maintenance of OIH and tolerance (Fig. 6m,n and Supplementary Note 5) . Thus, elimination of peripheral MOR signaling permits central opioid action to retain analgesic efficacy.
DISCUSSION
Nonselective pharmacological glial inhibitors, such as minocycline and propentofylline, are well known to attenuate opioid tolerance in rodents 16, 17 , and morphine has recently been proposed to act on MORs expressed by microglia to activate these cells and initiate OIH 10 . Using multiple histological approaches and highly sensitive RNA-seq of non-cultured, acutely purified adult spinal microglia, we did not find compelling evidence supporting MOR expression in microglia, contrary to previous findings from in vitro 38, 39 and in vivo studies 10, 40 . It is clear that glial cells under culture conditions exhibit an altered phenotype that can misrepresent certain aspects of their function in vivo, including ectopic expression of receptors 41, 42 . Note that, consistent with our findings, a large-scale RNA sequencing study in neurons and glia 43 , as well as ISH experiments 19 , have suggested that microglia do not express MORs. We also found that MOR KO mice showed intact morphine-induced microglial activation, but did not develop OIH, indicating that there is a dissociation between OIH and histological indications of microgliosis. The molecular mechanisms underlying the activation of microglia during chronic morphine treatment must therefore occur through a receptor other than MOR. Several alternate pathways for microglial activation underscore the complexity of the processes triggering microgliosis, highlighting the possibility that molecules released from neurons, in addition to or instead of direct action of morphine on microglia, might be responsible for the activation response observed following morphine treatment (Fig. 1c,d) . For example, the pattern-recognition receptor TLR4 on microglia may trigger their activation by binding damage-associated molecular patterns (DAMPs) released from neurons or by binding morphine itself; however, this last point remains controversial 10, 19 . Recent studies have instead suggested that TLR4 is not required for microglial activation by morphine 21 or for opioid tolerance and hyperalgesia 20 . Other proposed key mediators controlling microglial activation states include TLR2 (ref. 44) , the microglial ATP receptor P2X4 (ref. 40 ) and CSF1R 45 . Thus, we propose that opioid action at MORs expressed by nociceptors, and not by microglia, initiates downstream events in pain pathways (for example, in spinal, brain and descending circuits), which in turn could contribute to the molecular, synaptic and network-level adaptations that result in tolerance and OIH, as well as microglial activation and LTP 46 .
Opioid-induced spinal LTP at nociceptor synapses 28, 35 is now considered to be an essential contributor to OIH, and may also contribute to tolerance. However, the mechanisms underlying opioidinduced spinal LTP remain disputed, particularly the pre-28,36 versus postsynaptic 27 initiating events. Our optogenetic interrogation of synaptic transmission between TRPV1 nociceptors and dorsal horn neurons revealed that the deletion of presynaptic MORs not only eliminated DAMGO-induced depression of neurotransmission, but also abolished LTP, supporting the presynaptic origin hypothesis. We therefore propose that prolonged activation of MORs in nociceptors has predominantly pro-nociceptive effects during chronic opioid exposure 23, 35 , and initiates downstream plasticity throughout nociceptive circuits in the central nervous system to drive the development of tolerance and OIH 12 . We cannot draw definitive conclusions at this time regarding the cellular localization of MORs that contribute to tolerance and OIH within nociceptors (that is, MORs at the peripheral nerve terminals in the skin, along the nociceptor axons or at the nociceptor cell body). It should be noted, however, that repeated intradermal administration of MOR agonists 23 , which arguably only act on MORs at nociceptor peripheral terminals, or chronic administration of the peripherally acting opioid loperamide 47 are sufficient to induce OIH and/or antinociceptive tolerance.
Although opioids remain widely used in the treatment of perioperative, cancer and chronic non-cancer pain, recent re-evaluation Figure 6 Combination therapy of morphine and MNB delivers long-lasting antinociception, without the onset of tolerance, during perioperative and chronic pain states. (a,b,g,h) Time course for nociceptive hypersensitivity (a,g) and affective-motivational behaviors (b,h) following an orthotrauma (tibia fracture and bone pinning) or a peripheral nerve injury (CCI), and the effect of chronic saline (n = 10 for fracture, n = 5 for CCI), 10 mg/kg morphine (n = 10 per injury model) or 10 mg/kg morphine + 10 mg/kg MNB (n = 10 per injury model) treatments. Treatments were first administered on PID 7 and re-administered once daily until PID 14, with the exception that the saline group was administered acute morphine only on PID 7 and PID 14. of their side effects has highlighted dose escalation as a direct contributor to increased morbidity and mortality 4, 48 Opioid-induced hypersensitivity (%∆ thresholds, day 1 versus day 7)
Opioid-induced hypersensitivity (%∆ thresholds, day 1 versus day 7)
Opioid-induced hypersensitivity (%∆ duration, day 1 versus day 7)
Morphine antinociceptive tolerance (%∆ MPE, day 7 versus day 14)
Morphine antinociceptive tolerance (%∆ MPE, day 7 versus day 14) for opioid-induced constipation in non-cancer patients. Clinical trials have found no or minimal increase in pain or withdrawal symptoms after administration of these drugs 49, 50 . To date, no clinical studies have directly assessed the utility of peripheral MOR antagonists to reduce opioid analgesic tolerance. However, a recent Phase III report on MNB for opioid-induced constipation found that, compared with placebo-treated patients on a routine morphine schedule, patients taking MNB (12 mg once every other day) had stable or decreased morphine use after 1-4 weeks, with no increases in visual analog scale (VAS) pain scores 51 . In addition, the effects of orally administered prolonged-release oxycodone/naloxone combination on pain relief and opioid-induced constipation in patients with chronic pain resulted in significant reductions in pain scores compared with treatment with oxycodone alone 52 . Given that the opioid antagonist naloxone has very low oral bioavailability and extensive first pass metabolism, these results suggest that it acts, in this context, through blockade of peripheral opioid receptors. In contrast, one clinical study reported that MNB administration increased morphine consumption in patients in the first 4 h after surgery, but not later 53 . The particularly high dose of MNB (0.9 mg/kg) used, that is, sixfold higher than the current recommended therapeutic dose, and twice higher than a dose previously shown to have CNS effects 54 , might have resulted in blockade of CNS sites, as peripheral restriction of MNB is known to be dose dependent 55 . Consistent with this possibility, patients receiving a high dose of MNB, but not placebo, showed a higher incidence of nausea and vomiting 53 , indicating a withdrawal syndrome from blockade of central MORs that could explain the increased morphine consumption. Notably, this finding, along with preclinical studies using peripheral MOR antagonists, suggests that peripheral MOR signaling contributes to endogenous analgesia within hours of an injury 56 , whereas central MOR signaling mediates considerable endogenous analgesia over longer periods, from days to months after injury 57 . Indeed, we did not find that MNB increased pain associated with orthotrauma or nerve damage, indicating that endogenous analgesia mechanisms are unaffected by this treatment. We conclude that MORs expressed on primary afferent nociceptors drive the initiation of adverse counter-adaptations to opioids responsible for the onset of analgesic tolerance and OIH. Our data support the development of therapeutic strategies for disrupting peripheral MOR signaling to maintain adequate long-lasting pain control while limiting potentially harmful opioid dose escalation. The design of human trials aimed at rigorously evaluating the translational potential of opioid agonist/peripheral opioid antagonist combinations in appropriate patients with opioid-responsive pain conditions will be essential to the development of safer and more effective pain management strategies.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. To specifically ablate the MOR in primary afferent nociceptors (MOR cKO), mice bearing a conditional allele of the Oprm1 gene containing loxP sites flanking exons 2 and 3 generated previously 58 were crossed with transgenic mice expressing Cre under the control of the TRPV1 gene promoter, B6.129-Trpv1tm1(Cre)Bbm/J (TrpV1-cre, purchased from the Jackson Laboratory). Deletion of the Oprm1 exons 2 and 3 results in a frameshift that disrupts MOR function in MOR cKO mice. MOR cKO mice were born in the expected Mendelian ratios and showed no gross anatomical or behavioral defects, similar to the global MOR knockout mouse 8 . To confirm selective ablation of MOR in the DRG only of MOR cKO mice, we performed PCR on genomic DNA from DRG, spinal cord and brain using the following primers for the excised band forward primer (5′-ACCAGTACATGGACTGGATGTGCC-3′) and reverse primer (5′-GAGACAAGGCTCTGAGGATAGTAA -3′), which resulted in a 363-bp DNA fragment that was seen in DRG but absent in spinal cord and brain (Supplementary Fig. 3 ). Control subjects were littermate mice without the Oprm1 flox/flox alleles: Trpv1 Cre ;Oprm1 +/+ . For MOR cKO behavioral and electrophysiological studies, we used male and female mice (8-15 and 6-8 weeks, respectively). For all other experiments, we used male C57Bl6/J mice (8-15 weeks). Based on a power analysis, assuming 10-20% behavioral variability as in our previous work 23 Supplementary Fig. 13] , and Sigma SML0277 (data in Supplementary  Fig. 12) ). Drug vehicle and dilutions used 0.9% sodium chloride (Hospira NDC 0409-4888-10, Lot# 35-243-DK).
Subcutaneous injection. In lightly restrained, unanesthetized mice a 30G needle attached to a microsyringe was inserted through the skin and the drug (200-250-µl volume) is injected into the subcutaneous space.
Intrathecal injection. In lightly-restrained, unanesthetized mice, a 30G needle attached to a microsyringe was inserted between the L4 and L5 vertebrae, puncturing through the dura (confirmation by presence of reflexive tail flick), followed by injection of 2-5 µl as previously described 57 .
Behavioral testing. For consistency, one experimenter (G.C.) performed all in vivo drug administrations and behavioral testing with the exception of data in Figure 5a -e (G.C. and J.R.D.). All testing was conducted between 10:00 a.m. and 3:00 p.m. in an isolated, temperature-and light-controlled room. Mice were acclimated for 30-60 min in the testing environment within custom red plastic cylinders (4" D) on a raised metal mesh platform (24" H). The male experimenter's lab coat was present in the testing room for the first 30 min of acclimation, and then the experimenter entered the room for the final 30 min before commencement of testing to eliminate potential olfactory-induced changes in nociception 59 . The experimenter was blind to treatment and/or genotype throughout: all drugs were given to the experimenter in coded vials, and decoded only upon completion of testing. Mice of different genotypes were placed in randomized and coded holding cylinders for all sensory testing by V.L.T. or D.W., and only after testing was G.C. unblinded. Mice were randomized by simple selection from their homecage (five mice per cage) before testing, and assigned a number. For daily testing, a secondary experimenter (V.L.T.) changed the order of the mice to be tested; the primary experimenter (G.C.) was blind to this order. Mice were only excluded from the study if they were found to have extensive bodily wounds from aggressions with cage mates, as the presence of additional injuries introduces potential confounds, such as alterations to the endogenous opioid system 57 .
Classification of mouse behaviors into reflexive and affective-motivational nociceptive responses. To rigorously define the appearance of pain-like and pain-relief-like behaviors in nonverbal animals, we have adopted a strict taxonomy, as recommended by the International Association for the Study of Pain (IASP), so as not to overextend or inappropriately anthropomorphize rodent behaviors 60 . For example, we limit our description of pain-like behavior in mice to the use of words such as 'nociceptive, ' 'antinociceptive, ' 'hypersensitivity, ' 'nociception-induced affective-motivational behavior, ' etc., and reserve words such as 'pain, ' 'hyperalgesia, ' 'analgesia, ' etc. to descriptions of the human experience and the clinical effects of opioids. In mice, a cutaneous noxious stimulus can elicit several distinct behavioral responses 61 . (i) Withdrawal reflexes: rapid reflexive retraction or digit splaying of the paw that occurs in response to nociceptive sensory information, but ceases once the stimulus is removed and afferent nociceptive information stops. (ii) Affective-motivational responses: temporally delayed (relative to the noxious stimulus contact or removal of said stimulus), directed licking and biting of the paw (termed 'attending'), extended lifting or guarding of the paw and/or escape responses characterized by hyperlocomotion, rearing or jumping away from the noxious stimulus. Paw withdrawal reflexes are classically measured in studies of hypersensitivity, and involve spinal cord and brainstem circuits (as these behaviors are observed in decerebrate rodents only while the stimulus is in contact with tissue, but immediately cease once the stimulus is removed 62 ). By contrast, affective-motivational responses are complex behaviors requiring processing by limbic and cortical circuits in the brain, the appearance of which indicates the subject's motivation and arousal to make the aversive sensations cease, by licking the affected tissue, protecting the tissue, or seeking an escape route [62] [63] [64] [65] [66] [67] [68] .
Mechanical nociception assays. To evaluate mechanical reflexive hypersensitivity 57 , we used a logarithmically increasing set of eight von Frey filaments (Stoelting), ranging in gram force from 0.007 to 6.0 g. These were applied perpendicularly to the plantar hind paw with sufficient force to cause a slight bending of the filament. A positive response was characterized as a rapid withdrawal of the paw away from the stimulus filament within 4 s. Using the up-down statistical method 69 , the 50% withdrawal mechanical threshold scores were calculated for each mouse and then averaged across the experimental groups.
To evaluate mechanical-induced affective-motivational responses we used three von Frey filaments (0.07 g, 0.4 g, and 2.0 g). Each filament was applied for 1 s to the hindpaw, and the duration of attending behavior was collected for up to 30 s after the stimulation. Only one stimulation per filament was applied on a given testing session, to prevent behavioral sensitization that can result from multiple noxious stimulations and then averaging those responses.
Thermal nociception assays. To evaluate thermal reflexive hypersensitivity 61 , we used the tail-immersion test (temperature of the water bath was set to 48-52.5 °C, as indicated in the text or figures). The mouse was gently restrained and 2 cm of the tip of the tail was submerged in the water bath, and the latency (s) to reflexively withdraw the tail from the water was recorded as a positive nociceptive reflex response. A maximal cut-off of 45-60 s was set to prevent tissue damage. Only one tail immersion was applied on a given testing session, to prevent behavioral sensitization that can result from multiple noxious immersions and then averaging those responses.
To evaluate thermal-induced affective-motivational responses 61 , we used the hotplate test (plate temperature was set to 50-52.5 °C). Mice were placed on the plate and the latency (s) to the first appearance of an attending response (lick and/or bite at one or both hind paws) was recorded as a positive affective-motivational response. A maximal cut-off of 45 s was set to prevent tissue damage. Only one exposure to the hotplate was applied on a given testing session, in order to prevent behavioral sensitization that can result from multiple noxious exposures and then averaging those responses.
To evaluate affective-motivational responses to an acute, focal thermal stimulus 70 , we applied either a single, unilateral 50-µl drop of 55 °C water or acetone (evaporative cooling) to the left hind paw, and the duration of attending behavior was collected for up to 30 s after the stimulation. Only one stimulation per thermal drop was applied during a given testing session in order to prevent behavioral sensitization that can result from multiple noxious stimulations and then averaging those responses.
To evaluate affective-motivational responses to a sustained, inescapable noxious thermal stimulus mice were placed on a 52.5 °C hot plate for 45 s. A highspeed camera (on the side, level with the hot plate floor) was used to capture the movement, speed, velocity, and detailed reflexive and affective-motivational behaviors of the mice, as described above. As opposed to the standard hot-plate test, we scored all behaviors such as reflexive paw flinching (rapid flicking of the limb), paw attending (directed licking of the limb), paw guarding (intentional lift protection of the limb) and escape jumping for the duration of the trial. This allows us to analyze the high-speed videos, blinded to plate temperature or treatment, for the total time spent engaging in affective-motivational behaviors and the number of nociceptive reflexives, as opposed to the conventional metric of merely determining the latency to the first reflexive response. The time the animal spends engaging in these affective-motivational behaviors reflects the degree to which the animal translates nociceptive information into an aversive signal that instructs the animal to initiate behaviors that will lessen the aversive qualities of the on-going nociceptive information (i.e., licking the tissue, and protecting the tissue by guarding or seeking escape). To evaluate the presence of chronic morphine antinociceptive tolerance, mice are subjected to this modified hotplate assay on both the first day of morphine treatment and again on the last day of chronic morphine dosing.
Spinal cord slice preparation and electrophysiology. Adult mice (6-8 weeks old) were anesthetized with isoflurane, decapitated, and the vertebral column was rapidly removed and placed in oxygenated ice-cold dissection solution (in mM: 95 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 50 sucrose, 25 glucose, 6 MgCl 2 , 1.5 CaCl 2 , and 1 kynurenic acid, pH 7.4, 320 mOsm). The lumbar spinal cord was isolated, embedded in a 3% agarose block, and transverse slices (400 µm thick) were made using a vibrating microtome (Leica VT 1200S). Slices were incubated in oxygenated recovery solution (in mM: 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 25 glucose, 6 MgCl 2 , and 1.5 CaCl 2 , pH 7.4, 320 mOsm) at 35 °C for 1 h before recording. Patch-clamp recording in whole-cell configuration was performed at 32 °C on lamina I or lamina II outer-zone neurons visualized with an Olympus microscope (BX51WI age-MTI). Slices were perfused at ~2 ml/min with recording solution (in mM: 125 NaCl, 2.5KCl, 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 25 glucose, 1 MgCl 2 , 2 CaCl 2 , pH 7.4, 320 mOsm). Recordings were performed in voltage-clamp mode at a holding potential of -70 mV. Thick-walled borosilicate pipettes, having a resistance of 3-6 MOhm, were filled with internal solution (in mM: 120 potassium gluconate, 20 KCl, 2 MgCl 2 , 5 MgATP, 0.5 NaGTP, 20 HEPES, 0.5 EGTA, PH 7.25 with KOH, ~300 mOsm). All data were acquired using a Multiclamp 700B amplifier and pClamp10 software (Molecular Devices). Sampling rate was 10 kHz and data were filtered at 2 kHz. Analysis of eEPSC peak amplitudes was done with Clampfit software (pClamp10, Molecular Devices). Graphs and statistical analysis were generated with Igor Pro (Wave Metrics).
Optogenetic stimulation. To isolate the TRPV1 nociceptor mediated EPSCs, we crossed the TRPV1-Cre mice with Ai32 mice (Rosa-CAG-LSL-ChR2(H134R)-EYFP-WPRE) 71 to limit the ChR2 expression specifically to primary afferents. The TRPV1 nociceptor mediated EPSCs were evoked by blue light (0.2 ms, 0.03 HZ) generated by an LED Transmitted Light Source (Lambda TLED, Sutter). For all recordings, 10 µM bicuculline and 2 µM strychnine were included in the recording solution to eliminate the contribution of γ-aminobutyric acid type A (GABAA) or glycine receptors on the C-fiber or TRPV1 afferent mediated EPSC.
Immunohistochemistry. Mice (8-10 weeks) were transcardially perfused with 10% formalin in PBS. The brains, DRG (L3-L5), and spinal cord (lumbar cord L3-L5 segments) were dissected from the mice and cryoprotected in 30% sucrose in PBS. Tissues were then frozen in O.C.T. (Sakura Finetek). Tissue sections (30 m for the brains; 40 µm for spinal cord; and 10 µm for DRG) were prepared using a cryostat (Leica Biosystems) and blocked with PBS containing 5% normal donkey serum and 0.3% Triton X-100 for 1 h at 21-23 °C. The sections were then incubated with primary antibodies, indicated in each figure, at 4 °C, overnight. For the chicken anti-GFP antibody, the incubation was performed at 37 °C for 2 h. After extensive wash with PBS containing 1% normal donkey serum and 0.3% Triton X-100, sections were incubated with appropriate secondary antibody conjugated to AlexaFluor for 2 h at 21-23 °C. Images were collected under a Leica TCS SP5II confocal microscope with LAS AF Lite software (Leica Microsystems).
The following primary antibodies were used: anti-CD11b, Abd Serotec # MCA711G (rat, 1:1,000), anti-CGRP: Abcam ab22560 (sheep; 1:2,000); anti-GFP: Molecular Probes (rabbit; 1:1,000), anti-TRPV1: gift from D. Julius, UCSF (guinea-pig; 1:10,000); anti-MOR used in Figure 1 : Abcam 134054 (rabbit; 1:100), anti-MOR used in Figure 2 : gift from C. Evans, UCLA (rabbit; 1:300); anti-MOR used in Figure 1 : Abcam 10275 (rabbit; 1:100); anti-MOR: Neuromics GP10106 (guinea pig, 1:1,000). To identify IB4-binding cells, biotinylated IB4 Sigma L2140 (1:500) and fluorophore-conjugated streptavidin (Molecular Probes, 1:1,000) were used in place of primary and secondary antibodies.
ISH. ISH was performed using the Panomics QuantiGene ViewRNA tissue assay (Affymetrix/Panomics), as previously described 72 . The probe set provided by Affymetrix for hybridization to the mouse µ opioid receptor (Oprm1) coding region (NM_001039652) consists of 9 blocking probes and 40 short (15-25 base pair) oligonucleotide primers upon which a branched DNA amplification 'tree' is built. This methodology provides single-copy sensitivity and 8,000-fold signal amplification of each target mRNA through a unique branching amplification. The signal was detected by an alkaline phosphatase reaction with the Fast Red substrate, which was visualized by bright field or fluorescent microscopy. To combine Oprm1 ISH with immunohistochemistry for microglial marker CD11b, the following protocol was developed: C57BL/6J wild-type mice were deeply anesthetized with isoflurane and transcardially perfused with 0.1M PBS followed by 10% formalin in PB. Lumbar DRGs were dissected, cryoprotected in 30% sucrose overnight and then frozen in OCT. Tissue was then sectioned at 12-14 µm onto Superfrost Plus slides and kept at -80 °C until use. Slides were thawed and then placed directly into 10% formalin for 10 min and then subsequently processed according to the manufacturer′s protocol. We determined that protease treatment for 12 min was optimal and following this, slides were incubated for 3 h with the RNA probe set at 40 °C. After washing, pre-amplifier hybridization and hybridization with an alkaline phosphatase-based method to detect the ISH probe, the slides were blocked in 5% normal donkey serum/0.1-M PBS (without Triton X-100) for 1 h at 21-23 °C and then processed for immunohistochemistry as described above.
Microglia RNA library construction and sequencing. Adult (P60) C57BL/6J mice were perfused with ice-cold PBS and L4-L6 lumbar segments of spinal cords were isolated using ribs and vertebra as landmarks. Spinal cords that retained any detectable redness (indicating presence of blood) after perfusion were discarded. Lumbar segments from 4 to 15 mice per group were pooled and mechanically dissociated in HBSS (Gibco) containing 0.5% Glucose, 15 mM HEPES pH 7.5, and 125 U/ml DNaseI (Sigma). Dissociated tissue was subjected to MACS myelin removal (Myelin Removal Beads II, Miltenyi) followed by CD11b selection (CD11b Microbeads, Miltenyi) according to the manufacturer's instructions, except all centrifugation steps were shortened to 30 s at 10,000 r.c.f. The isolation was performed rapidly (less than 3 h) and care was taken to keep the cells chilled throughout to minimize gene expression changes caused by the procedure.
Total RNA was extracted from CD11b-positive cells using the RNeasy Plus Micro Kit (Qiagen). For each replicate, 10 ng of high-quality total RNA (RIN > 9.0) was used to prepare a poly-A enriched cDNA library using the SMARTer Ultra Low Input RNA Kit for Sequencing-v3 (Clontech). Supplemental morphine and saline treatment RNA libraries were prepared with Smart-Seq2 (ref. 73 ). Libraries were modified for sequencing using the Nextera XT DNA Sample Preparation Kit (Illumina) with 300 pg of cDNA as input material. Libraries were sequenced using the Illumina Nextseq to obtain 75-bp paired-end reads. Two libraries for each condition were prepared and sequenced independently for an average of 15.7 million reads per group.
Sequencing reads were mapped to the UCSC mouse reference genome mm10 essentially as previously described 43 . Mapping was accomplished by using HISAT 74 version 2.0.3 via the Galaxy platform (http://usegalaxy.org), resulting in a minimum 70% concordant pair alignment rate. Wiggle plots were generated using BEDTools 75 and BedGraph-to-bigWig converter in Galaxy and the UCSC genome browser. Transcript FPKM (fragments per kilobase of transcript sequence per million mapped fragments) values were obtained using Cufflinks 76 version 2.2.1 with the iGenomes mm10 reference annotation.
Pain models. Neuropathic pain. Two bilateral peripheral nerve injuries were performed: chronic constriction injury (CCI) 77 and complete transection of the sciatic nerve 78 . Briefly, adult C57BL6J mice were anesthetized with isoflurane, and one sciatic nerve at a time was exposed at mid-thigh level. For CCI, two 5-0 silk sutures were loosely tied around the nerve about 2 mm apart. In the complete transection model, a 2-mm portion of the nerve was excised. The wound was closed with tissue adhesive (Vetbond) and the procedure was repeated on the other side. 2 d or 7 d after injury, spinal cords were collected for RNAseq as described above. For behavior, injuries were performed unilaterally and mice were tested beginning 7 d after the surgery.
Orthotrauma inflammatory pain. Mice were anesthetized with isoflurane and underwent a distal tibia fracture and an intramedullary pin fixation in the right leg, as previously described 79 . Briefly, to make the shaft for the bone pinning, a small hole was made in the proximal tibia and a 27 G needle was inserted down the medullary axis of the bone, and then removed. Next, the distal tibia was scored with a bone saw and fractured. To set the fracture, the 27 G needle was re-inserted into the intramedullary space, through the proximal tibia, and advanced across the fracture site to the distal portion of bone. The wound was closed with sterile staples. For behavior, mice were tested beginning 7 d after the surgery.
Data and statistical analyses. All experiments were randomized and performed by a blinded researcher. Researchers remained blinded throughout histological, biochemical and behavioral assessments. Groups were unblinded at the end of each experiment before statistical analysis. Data are expressed as the mean ± s.e.m. Data were analyzed using a Kruskal-Wallis or Student's t tests, or ordinary or repeated measures one-way or two-way ANOVA, with a Bonferroni post hoc test, as indicated in the main text or figure captions, as appropriate. For doseresponse hyperalgesia studies the best-fit line was generated following nonlinear regression analysis based on the % maximum possible effect (MPE) for each mouse; calculated as: MPE = ((drug induced threshold -basal threshold)/basal threshold) × 100.
